|
Symposium
[Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
Speakers:
Aihua Fu, NVIGEN; Emily Miyashita-Lin, Cellentia; Chaitanya Gupta, Probius; Joseph de Rutte, Partillion Bioscience; Andrew Chang, DeepSeq.AI; Xiaoxi Wei, X-Therma Inc.; Samuel Tia, Correlia Biosystems
Organizers:
Shian Jiun Shih (Cellentia, Inc.), Aihua Fu (NVIGEN), Alex Yang (Vir Biotechnology)
Date:
2024-04-12
Time:
8:30-13:30 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-04-11
(it will close sooner if the seating cap is reached)
About the Topic
The abstract of this symposium:
The era of one-size-fits-all pharmaceuticals is fading. Today, the drug development landscape brims with groundbreaking modalities - from gene and cell therapies to mRNA and antibody-drug conjugates (ADCs) armed with radiotherapy. This transformative journey demands equally disruptive tools to streamline and accelerate research. Join us at this symposium as we explore the frontier of technology propelling the discovery of next-generation therapeutics. This symposium will showcase a diverse arsenal of tools designed to empower every stage of drug development. Topics include single-cell analysis, AI-based protein design, cancer organoids for drug screening, multiplex assays sans detecting agents, and sensitive NGS/multiomic biomarker profiling assays revealing previously hidden disease complexity. These advancements reflect the continuous pursuit of innovation, accelerating the quest for more effective, targeted, and ultimately, transformative therapeutic solutions.
|
Time (PT)
|
Topic
|
Speaker
|
|
8:30-8:40 am
|
PBSS Welcome and Introduction
|
Shichang Miao, PhD, PBSS
|
|
8:40-9:15 am
|
Novel Non-Invasive Organoid Platform from Cancer Patient Circulating Tumor Cells for Drug Screening and Monitoring
|
Emily Miyashita-Lin, Director, Cellentia
|
|
9:15-9:50 am
|
Expand Your Functional Toolkit: Nanovial Assays for Drug Discovery and Development
|
Joseph De Rutte, CEO and Co-founder, Partillion Bioscience
|
|
9:50-10:25 am
|
Evaluation of the PIXI™ Automated Platform for Rapid, Micro-volume PK Measurements
|
Samuel Tia, CSO and Co-founder, Correlia Biosystems
|
|
10:25-10:35 am
|
Break
|
-
|
|
10:35-11:10 am
|
Crack the Biomarker Code: Accelerate Drug Development with NVIGEN's Precision Medicine Biomarker Profiling Assays
|
Aihua Fu, CEO and Co-founder, NVIGEN
|
|
11:10-11:45 am
|
Simplifying Bio Analytical Assay Development: The Quantum Electrochemical Spectroscopy (QES) Approach
|
Chaitanya Gupta, CTO and Co-founder, Probius
|
|
11:45-12:20 pm
|
A Tale of a Golden Shovel in the Gold Rush: Next-Generation DMSO-Free & Serum-Free Biopreservation for Cell & Gene Therapies and Engineered Tissues Manufacturing And Processing
|
Xiaoxi (Sofie) Wei,CEO and Co-founder, X-Therma
|
|
12:20-12:55 pm
|
Unlocking the Potential of Explainable AI in Designing Functional Protein Libraries
|
Andrew Chang,CEO and Co-founder, DeepSeq AI
|
|
12:55-1:25 pm
|
Q&A and Panel discussion
|
All Speakers
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|